SLC5A2 and type 2 diabetes mellitus: Although the CONFIDENCE study (NCT NCT05254002), which is investigating the combination of empagliflozin with finerenone in subjects with CKD and T2D, is currently underway, to date no clinical trial has specifically analyzed the effect of combining an SGLT2 inhibitor with finerenone.